May 21, 2020

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

May 11, 2020

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities

May 4, 2020

Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

April 21, 2020

Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer

February 27, 2020

Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020 Copy

February 20, 2020

Appili Therapeutics Announces Closing of Public Offering of $10,250,000

February 14, 2020

Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering

February 13, 2020

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

February 12, 2020

Appili Therapeutics Announces Overnight Marketed Equity Offering

January 28, 2020

Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats

January 27, 2020

Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors

January 7, 2020

Appili Celebrates a Notable 2019 and Looks Ahead to Significant Milestones in 2020